Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | CCKAR | P32238 | 13/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781827 | 0.90 | GABRA2 (0.53) | ALDH1A1HTTGABRA2GABRB2CCKAR | |
| SCHEMBL5782229 | 0.84 | GABRA2 (0.51) | GABRA2GABRB2CCKAR | |
| SCHEMBL26986788 | 0.82 | GABRA2 (0.56) | GABRA2GABRB2CCKAR | |
| SCHEMBL5782557 | 0.81 | GABRA2 (0.56) | GABRA2GABRB2CCKAR | |
| SCHEMBL5781289 | 0.80 | GABRA2 (0.56) | ALDH1A1GABRA2GABRB2SMN1; SMN2 | |
| SCHEMBL5782633 | 0.79 | CCKAR (0.53) | GABRA2GABRB2CCKAR | |
| SCHEMBL2918283 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HTTPOLB | |
| SCHEMBL5784621 | 0.76 | CCKAR (0.50) | GABRA2GABRB2CCKAR | |
| SCHEMBL5780829 | 0.76 | CCKAR (0.52) | GABRA2GABRB2CCKAR | |
| SCHEMBL5783585 | 0.75 | GABRA2 (0.83) | ALDH1A1GABRA2GABRB2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | ALDH1A1 251/4885HTT 2548/4885GABRA2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.